Kyverna Therapeutics Revenue vs. Net Income
| KYTX Stock | 9.07 0.41 4.73% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 2.5 M |
For Kyverna Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kyverna Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kyverna Therapeutics Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kyverna Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kyverna Therapeutics Common over time as well as its relative position and ranking within its peers.
Check out Correlation Analysis. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kyverna Therapeutics. If investors know Kyverna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kyverna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kyverna Therapeutics is measured differently than its book value, which is the value of Kyverna that is recorded on the company's balance sheet. Investors also form their own opinion of Kyverna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kyverna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kyverna Therapeutics' market value can be influenced by many factors that don't directly affect Kyverna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kyverna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kyverna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kyverna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kyverna Therapeutics Net Income vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Kyverna Therapeutics's current stock value. Our valuation model uses many indicators to compare Kyverna Therapeutics value to that of its competitors to determine the firm's financial worth. Kyverna Therapeutics Common is currently under evaluation in revenue category among its peers. It is rated below average in net income category among its peers . At this time, Kyverna Therapeutics' Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kyverna Therapeutics' earnings, one of the primary drivers of an investment's value.Kyverna Revenue vs. Competition
Kyverna Therapeutics Common is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 97.93 Million. Kyverna Therapeutics adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.
Kyverna Net Income vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Kyverna Therapeutics |
| = | null |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Kyverna Therapeutics |
| = | (127.48 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Kyverna Net Income Comparison
Kyverna Therapeutics is currently under evaluation in net income category among its peers.
Kyverna Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Kyverna Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kyverna Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Kyverna Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Kyverna Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 120.8 K | 126.8 K | |
| Net Interest Income | 17.5 M | 18.4 M | |
| Interest Income | 17.7 M | 18.5 M | |
| Operating Income | -128.3 M | -121.9 M | |
| Net Loss | -114.7 M | -109 M | |
| Income Before Tax | -114.7 M | -109 M | |
| Total Other Income Expense Net | 17.4 M | 18.3 M | |
| Net Loss | -114.7 M | -109 M | |
| Income Tax Expense | -114.7 M | -109 M | |
| Net Loss | (3.82) | (3.63) | |
| Income Quality | 1.03 | 1.06 |
Kyverna Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Kyverna Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kyverna Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kyverna Therapeutics' important profitability drivers and their relationship over time.
Kyverna Therapeutics Earnings Estimation Breakdown
The calculation of Kyverna Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Kyverna Therapeutics is estimated to be -0.926375 with the future projection ranging from a low of -1.0025 to a high of -0.856875. Please be aware that this consensus of annual earnings estimates for Kyverna Therapeutics Common is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1 Lowest | Expected EPS | -0.86 Highest |
Kyverna Therapeutics Earnings Projection Consensus
Suppose the current estimates of Kyverna Therapeutics' value are higher than the current market price of the Kyverna Therapeutics stock. In this case, investors may conclude that Kyverna Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Kyverna Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 6 | 90.68% | -0.85 | -0.926375 | -3.73 |
Kyverna Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Kyverna Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Kyverna Therapeutics Common predict the company's earnings will be in the future. The higher the earnings per share of Kyverna Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Kyverna Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Kyverna Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Kyverna Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Kyverna Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Kyverna Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-13 | 2025-09-30 | -1.02 | -0.85 | 0.17 | 16 | ||
2025-08-12 | 2025-06-30 | -1.02 | -0.97 | 0.05 | 4 | ||
2025-05-14 | 2025-03-31 | -1.0027 | -1.03 | -0.0273 | 2 | ||
2025-03-27 | 2024-12-31 | -0.95 | -0.8678 | 0.0822 | 8 | ||
2024-11-13 | 2024-09-30 | -0.84 | -0.8 | 0.04 | 4 | ||
2024-08-12 | 2024-06-30 | -0.78 | -0.67 | 0.11 | 14 | ||
2024-05-14 | 2024-03-31 | -0.84 | -1.12 | -0.28 | 33 | ||
2024-03-26 | 2023-12-31 | -3.23 | -26.86 | -23.63 | 731 |
Use Kyverna Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kyverna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kyverna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Kyverna Therapeutics Pair Trading
Kyverna Therapeutics Common Pair Trading Analysis
The ability to find closely correlated positions to Kyverna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kyverna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kyverna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kyverna Therapeutics Common to buy it.
The correlation of Kyverna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kyverna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kyverna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kyverna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Kyverna Therapeutics position
In addition to having Kyverna Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Commodities ETFs Thematic Idea Now
Broad Commodities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Commodities ETFs theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Commodities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Kyverna Stock Analysis
When running Kyverna Therapeutics' price analysis, check to measure Kyverna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kyverna Therapeutics is operating at the current time. Most of Kyverna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kyverna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kyverna Therapeutics' price. Additionally, you may evaluate how the addition of Kyverna Therapeutics to your portfolios can decrease your overall portfolio volatility.